Can-Fite BioPharma American Depositary Shares
CANF
11 hedge funds and large institutions have $1.35M invested in Can-Fite BioPharma American Depositary Shares in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 11 → 11 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
75% less capital invested
Capital invested by funds: $5.35M → $1.35M (-$4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55.8K |
| 2 |
Morgan Stanley
New York
|
+$47.8K |
| 3 |
Jane Street
New York
|
+$12K |
| 4 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$12K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$7.97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.96M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.48M |
| 3 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$352K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$15K |
| 5 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$4K |
CANF Hedge Fund Activity: Q2 2018 in Review
11 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2018, worth a combined $1.35M — down 75% from $5.35M a quarter earlier.
Fund positioning in CANF was balanced in Q2 2018: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $55.8K. The largest seller was Anson Funds Management, exiting entirely with an estimated $1.96M sold.
- 11 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $1.35M of Can-Fite BioPharma American Depositary Shares stock for Q2 2018, down 75% quarter-over-quarter.
- 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2018 and 5 closed out, a net change of 0 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2018 was Susquehanna International Group, an estimated $55.8K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2018 was Anson Funds Management, an estimated $1.96M sold.
Based on aggregated 13F filings for Q2 2018.